Understanding the molecular basis of disease
Without quantitative analysis, traditional pathology offers only part of the diagnostic story. Cellfluidics' platform technology provides the pathologist with information about the patient's own cancer cells. By providing high-throughput analysis of minute sample quantities at a low cost, Cellfluidics enables the clinician the ability to apply targeted treatment plans patient by patient.
News
April 15th, 2009
Cellfluidics Founder, Prof. Hsian-Rong Tseng gives invited about new MiC data at Clinical Neurosurgical Symposia at UCLA
April 6th, 2009
UCLA Pathology Chair Jonathan Braun, MD forsees Cellfluidics’ platform as resolving "the unment need and urgency of measuring the biologic pathways active in the cancer tissue of the individual patient"
March 18th, 2009
UCLA oncologist Antoni Ribas, MD partners with Cellfluidics to is develop a novel MiC assay for melanoma applications